What are AIDS and HIV?

AIDS stands for acquired immunodeficiency syndrome to attach a condition 1st Reported in the United States in 1981, which is now a major global epidemic.

AIDS is HIV (Human Immunodeficiency Virus). By killing or damaging cells of the body's immune system, HIV progressively destroys the body's ability to fight infections and certain cancers. The term AIDS applies to the most advanced stages of HIV infection.

How is the spread of HIV?

There are different ways that HIV can be passed from person to person, including:

* Having unprotected sex with someone who is infected
* With needles or syringes used by the people who are infected
* Receiving infected blood products or organs transplanted (Since 1985, the United States actively testing all blood donations for HIV; Therefore, the risk of HIV in this way in the United States is now extremely low.)
* Transmission from mother to child "€" An infected mother can the virus to their developing fetus during pregnancy, during birth or through breastfeeding.

If you have a sexually transmitted disease may be at higher risk of infection with HIV during sex with an HIV-infected partner.

There is no evidence that HIV is spread through contact with saliva or by casual contact work, such as shaking hands or hugging or the distribution of food dishes, bedding and towels, swimming pools, telephone or toilet seats. HIV is not from biting insects such as mosquitoes or bugs.

What is it for the treatment of HIV / AIDS?

Although AIDS, when for the first time there were only a few treatments, researchers have developed drugs that can help fight both HIV and related infections and cancers associated with. Advances in treatment have improved survival and decreased progression of HIV disease in the developed countries like the United States, where antiretroviral drugs are available.

For more information, please treatment from the National Institute of Allergy and Infectious Diseases at NIH. The NIH is currently conducting many clinical studies related to HIV / AIDS testing and treatment therapies. These studies are sponsored and co-sponsored by several institutions, including the NICHD.

The NICHD supports and conducts research related to HIV / AIDS in certain groups of people, including pregnant and non-pregnant women, infants and children, adolescents and young adults. The information below applies to the groups.

How does the fight against HIV / AIDS on women?

According to the Joint United Nations Program on HIV / AIDS (UNAIDS), 19.2 million women with HIV / AIDS live in the whole world. In many countries, the rate of HIV infection among women is rising faster than in any other group.

Worldwide, more than 80% of HIV infections are from heterosexual sex (vaginal sexual intercourse); Women are especially at risk of HIV through this kind of contact. HIV is increasing dramatically the African American and Hispanic women.

Although most of the signs and symptoms of HIV infection are similar in men and women, some are specifically designed for women. For example:

* Vaginal yeast infections can be chronic, severe and difficult to treat, in the women with HIV infection than women who are not infected.
* Pelvic inflammatory disease, an infection of the female genital organs, including more frequent and severe in women with HIV infection.
* Human papillomavirus (HPV) infection, the cause of genital warts, often in HIV-infected women, and can cause lesions before cancer of the cervix or cancer of the cervix.

The NICHD, together with other institutions, supports studies to determine which aspects of HIV, especially for women and the best treatment options for these symptoms.

How does HIV affect pregnant women and children?

Women can HIV to their babies during pregnancy, during birth or through breastfeeding.

But there are effective ways to prevent the spread of mother to child transmission of HIV:

* Taking anti-HIV drugs during pregnancyâ € "either a drug called zidovudine, or AZT alone or in combination with other drugs called highly active antiretroviral therapy (HAART)" € "a mother can significantly reduce the chances that their children get HIV infected.
* Delivering the child by caesarean section, before the mother € ™ s, uterine rupture membranes of course, reduces transmission, possibly during the birth. The use of antiretroviral drugs during pregnancy and delivery, combined with a Caesarean section among women with certain levels of HIV in their blood, the chance that the child will be infected to less than 2%.
* Avoidance of breastfeeding by an HIV-infected mother. HIV can affect babies via breast milk of mothers infected with the virus. The American Academy of Pediatrics recommends that in countries like the United States, where infant formula is safe and is often available and affordable, HIV-infected women their infants commercially available formula instead of breastfeeding.

About one quarter to one half of all untreated pregnant women infected with HIV in the infection to their babies. HIV infection of newborns is very rare in the United States, because women are tested for HIV during pregnancy and women with HIV infection receive antiretroviral drugs during pregnancy, caesarean section, if the supply of HIV in the blood are high, it is recommended, and not to breast-feed their infants and toddlers.

How does HIV affect children and adolescents?

It is estimated that approximately 10,000 children are living with HIV infection in the United States. In the United States, the number of children born with HIV infection has dropped dramatically from about 2,000 per year to less than 200 per year by the identification of HIV infection in pregnant women, and the use of anti-HIV drugs during the pregnancy, caesarean delivery, and the avoidance of breastfeeding.

Unlike the United States, the mother-to-child transmission in developing countries remains a major problem; About 700,000 children newly infected with HIV each year, as most women are not screened for HIV during pregnancy, combating HIV drugs are not available, and safe alternatives to breast-feed is not available.

Before 1985, when screening of the nation's blood supply for HIV started, some children and adults were infected by transfusions of blood or blood products contaminated with HIV, but it is now rare in the United States.

In contrast to the dramatic decline in mother-to-child transmission of HIV infection, the number of cases of HIV infection among adolescents and young adults continue to increase in the United States. Approximately one third to one half of new HIV infections in the United States are among teenagers and young adults.

Most HIV-infected youths and young adults are exposed to the virus through unprotected sex; Some teenagers and young adults are infected through injecting drug use. In addition, an increasing number of children who were infected as infants are now surviving until adolescence.

Acquired Immune Deficiency Syndrome: The Facts

Introduction

The first cases of acquired immune deficiency syndrome (AIDS) were reported in the U.S. in June of 1981. The occurrence of the syndrome among homosexual men, intravenous (IV) drug abusers and, later, blood transfusion recipients and persons with hemophilia suggested a transmissible agent as the cause. In 1984, scientists identified a retrovirus, human immune deficiency virus (HIV), also known as human T-Iymphotropic virus type III/lymphoadenopathy, associated virus (HTLV-III/LAV), as the primary cause of AIDS. In 1985, screening tests to detect antibodies to HIV were licensed, allowing identification of infected individuals and the screening of the blood supply. Researchers have been able to map the genetic structure of HIV and to demonstrate the nature of the immune defect. Ongoing research is aimed at identifying risk factors and preventive strategies, evaluating antiviral drugs, developing drugs to augment the immune system, and developing a vaccine.

An estimated 1,000,000 Americans have been infected by the HIV virus. The virus has been isolated from various bodily fluids including blood, semen, saliva, tears, urine, breast milk and cerebrospinal fluid. Transmission of HIV occurs primarily through four major routes: sexual contact, intravenous drug use, blood transfusions and perinatal contact with an infected mother. The screening of donated blood since 1985 for HIV antibodies has virtually eliminated blood transfusion as a risk for acquiring AIDS in the U.S. 95% of the cases of AIDS reported in the U.S. have belonged to the following high risk groups: homosexual and bisexual men, 73%; IV drug abusers, 17% (11% of homosexual and bisexual men also inject drugs); blood transfusion recipients, 2%; persons with blood clotting disorders or hemophilia, 1%; heterosexual contacts of persons in the above groups, 1%; and infants born to mothers with AIDS or HIV infection, 1%.

All persons with AIDS or with antibodies to HIV are considered carriers of the virus and capable of transmitting it to others. It is believed that most people with antibodies to HIV will remain free of AIDS symptoms. The ratio of persons infected with HIV to those with AIDS is estimated currently at between 100:1 to 50:1. The three-year incidence of AIDS among persons with the HIV infection ranges from 8% to 34.2% in selected municipal studies. Estimates are that 10% to 30% of infected persons will develop AIDS within 5 years. For persons who develop AIDS, the overall fatality rate in April of 1986 was 54%. At the end of two years following diagnosis of AIDS, however, the fatality rate was over 75%. At five years, the fatality rate was about 90%.

90% of AIDS patients are between 20-49 years of age. The loss of years of potential life before age 65 due to AIDS is nearly the same as for cancer in single men 25-44 years of age. The economic costs of AIDS are considerable, totalling an estimated $4.1 billion in 1985. Data cited here are changing rapidly and represent the situation only as of 1986.

Prevalence

Prevalence of HIV Infection

As of 1987, an estimated 1.5 million Americans were infected with the HIV virus.

In 1984-1985, the prevalence of the HIV antibody in populations of homosexual men ranged from a low of 44% in Washington, D.C. to 65% in New York City to a high of 68% in San Francisco.

In 1984, the prevalence of the HIV antibody in population of IV drug users ranged from a low of 9% in San Francisco to a high of 68% in New York City.

In 1983-1985, the prevalence of the HIV antibody in populations of hemophilia patients ranged from 46% to 75%.

The period of time between known exposure to the HIV virus and seroconversion ranges from 19 days to 12 weeks.

AIDS in adults usually develops more than two years after HIV infection and may appear more than five years after seroconversion.

The three-year incidence of AIDS among all HIV seropositive subjects in a study of five cohorts (three groups of homosexual men, one group of IV drug users and one group of hemophilia patients) ranged from 8.0% to 34.2%.

Prevalence of AIDS

A total of 21,517 cases of AIDS were reported in the United States by June 9, 1986.

AIDS cases have been reported from all 50 states, the District of Columbia and 3 U.S. territories.

Although the number of new AIDS cases continues to increase each year, the rate of increase has diminished, as shown below.

The length of time required for a doubling of the cumulative number of AIDS cases in the U.S. has increased from 5 months in 1982 to 11 months in January, 1986.

The annual incidence rate of AIDS in the U.S. has increased from 0.11 cases per 100,00 persons in 1981 to 1.43 cases per 100,000 persons for the year ending May 31, 1984.

The prevalence of AIDS in the U.S. as of June 9, 1986, was 94.5 cases per million population. Broad geographical variation exists, with the highest prevalence rates recorded in New York City (722.0 cases per million) and San Francisco (684.8 cases per million). Those two cities accounted for 41% of all 21,517 AIDS cases reported in the U.S. by June 9, 1986.

In the U.S., 95% of AIDS cases have occurred to persons belonging to one or more groups known to be at high risk for AIDS, including homosexual or bisexual males, intravenous drug abusers, hemophilia or coagulation disorder patients, blood transfusion recipients or heterosexual contacts of persons with AIDS or at risk of AIDS.

Of the 6% of AIDS cases initially reported without identifying risk factors, about 33% are persons from countries where heterosexual transmission accounts for many AIDS cases. Further interviewing of available members of the remaining group identified risk factors for all but 33%. Thus, less than 2% of all AIDS cases ultimately remained without identifiable risk factors.

Opportunistic infections occur in all AIDS patients. To date in the U.S., 58% of AIDS patients have had Pneumocystis carinii pneumonia (PCP), 17% have had Kaposi’s sarcoma (KS), 5% have had both PCP and KS and 19% have had other opportunistic infections.

Kaposi’s sarcoma has been reported in over 34% of homosexual men with AIDS, but in only 6% of AIDS patients in all other groups.

Mortality from AIDS

As of June 9, 1986, 11,713 people died in the U.S. from AIDS, representing 54% of all known cases.

The case fatality rate is over 75% for persons diagnosed with AIDS for two years or more.

In a follow-up of approximately 3,600 cases of AIDS in New York City and State, the median survival time for gay men was 10 months and for IV drug abusers 7 months.

The median survival of those AIDS patients with Kaposi’s sarcoma was 14 months, those with Pneumocystis carinii pneumonia was 7 months and those with other opportunistic infections was 6 months.

Since about 90% of AIDS patients are between 20-49 years old, AIDS results in a disproportionate number of years of potential life lost (YPLL) before age 65. In single men ages 25-44 years in the U.S., AIDS caused nearly as many YPLL in 1984 (32,300) as did cancer (39,500) in 1980. In Manhattan and San Francisco in 1984, AIDS was the leading cause of YPLL among 25-44 year-old men with more YPLL than for accidents, homicide, suicide, and cancer combined.

Modes of Transmission

All persons with AIDS or with antibodies to HIV are considered carriers of the virus, capable of transmitting the infection to others.

Although HIV has been isolated from the blood, semen, saliva, tears, urine and breast milk of infected individuals, the only known transmission has been via blood and semen. Studies of nonsexual household contacts of AIDS patients indicate that casual contact with saliva and tears does not result in transmission of infection.

HIV infection can persist even in asymptomatic individuals for at least several years. Retrovirus infections in animals persist for life. The presence of HIV antibody is presumptive evidence of current infection and infectibility.

In most cases, HIV appears to have been transmitted through one or more of four routes: sexual contact, intravenous drug administration with contaminated needles, administration of blood and blood products, and passage of the virus from infected mothers to their unborn babies.

After four years of close observation of AIDS in the U.S., no evidence exists showing the transmission of HIV infection or AIDS through food, by arthropods, or from casual contact. Similarly, no cases of AIDS or HIV transmission have been attributed to the use of immunoglobulins or the hepatitis B vaccine.

The risk of HIV transmission through blood or blood products transfusion has been virtually eliminated by current practices, which include screening of donated blood for HIV antibodies and heat treatment of clotting factor concentrates.

The risk of perinatal transmission of HIV by infected mothers is not known precisely, but was observed in one study to be as high as 65%.

No known transmission of HIV infection to household contacts of infected persons has been detected when the household contacts have not been sex partners or infants of infected mothers.

No known transmission of HIV infection has occurred from the preparation or serving of food or beverages. No known risk of transmission to coworkers, clients, or consumers exists from HIV-infected workers in other worksites (e.g., offices, schools, factories, construction sites).

The risk of acquiring HIV infection from a needlestick exposure to a source patient is much less than 1%. For comparison, the risk of hepatitis B infection following a needlestick from a hepatitis B carrier ranges from 6%-30%.

AIDS Outside the United States

In Europe, a cumulative total of 1,573 cases of AIDS have been diagnosed through September 1985. The highest prevalence rates were recorded in Belgium (11.9 per million), Switzerland (11.8 per million) and Denmark (11.2 per million), but were far below the estimated prevalence of AIDS in the U.S. in September 1985 of 60.0 per million.

In Europe, 92% of the AIDS patients as of September 1985 were males and 88% were between 20-49 years of age. Of the total European AIDS cases, 69% were homosexual or bisexual men, 6% were IV drug abusers, 2% were both of the above, 3% were hemophilia patients, 2% were transfusion recipients without other risk factors, 2% were unknown, and 11% had no known risk factors. Of those without identifiable risk factors, up to 72% were from countries where heterosexual transmission of HIV occurs commonly.

The Pan-American Health Organization reports 1,685 cases of AIDS in the Americas outside the U.S. through December 31, 1985. The majority of those cases were from Brazil (540), Canada (435) and Haiti (377).

Cases of AIDS have been reported in residents of nearly 20 African countries, but studies of AIDS have been conducted primarily in Zaire and Rwanda. In Zaire, the male-to-female ratio was approximately 1:1 and the annual incidence was estimated at 17-40 per 100,000 population. In the U.S., the male-to-female ratio among adults is currently 14.2:1. In 1984, the annual incidence of AIDS in the U.S. among single males was 14.3 per 100,000, and among the general population, 1.4 per 100,000.

HIV and AIDS in Homosexual and Bisexual Men

In a cohort of 6,875 homosexual and bisexual men in San Francisco, the prevalence of HIV antibodies had reached 73.1% by August, 1985.

In the San Francisco cohort, 3.8% of the entire group and 5.2% of those with HIV antibodies had developed AIDS by August, 1985.

Two-thirds of the men in the San Francisco cohort study who had HIV infections for over five years had not developed AIDS or AIDS-related illness.

The seroprevalence of HIV antibody among a group of homosexual males in New York City was 65% in a 1985 study.

The three year incidence of AIDS was 34.2% in a, cohort of HIV seropositive homosexuals in Manhattan.

Intervention Data

Changes in Sexual Behavior Among High Risk Groups

Surveys of risk factors for HIV infections among gay and bisexual men in San Francisco revealed that the percentage of persons with more than one sexual partner during the 30 days prior to the survey decreased from 49% in August, 1984, to 26% in April, 1985. The percentage of persons who were monogamous, celibate or had no unsafe sexual activity outside a primary relationship increased from 69% in August, 1984, to 81% in April, 1985. (In this study, an unsafe sexual practice included anal intercourse without a condom and oral sex with exchange of semen.)

Cases of rectal gonorrhea in men attending the San Francisco City Health Department clinics declined 73% between 1980-1984.

Between 1980-1983, rates of rectal and pharyngeal gonorrhea in men in Manhattan decreased 59%.

Use of Health Services

The initial hospitalization of AIDS patients entails a mean length of stay of 31 days. Rehospitalization for new or recurrent opportunistic infections is frequent.

A New York City study found that 14% of AIDS patients died during the initial hospitalization, 35% spent less than 30% of the time in the hospital after the initial hospitalization, 16% spent between 30%-50% of the time hospitalized and the remaining 35% spent more than 50% of the time in the hospital.

It is estimated that the first 10,000 patients with AIDS will spend a total of 1,677,900 days in the hospital.

A California study reported that AIDS patients had an average of 6.4 hospitalizations at an average length of stay of 14 days over an 18-month average lifespan.

Economic Impact

An estimated $147,000 is spent on the entire hospital care of each AIDS patient.

A study of the economic costs of AIDS estimated that in 1984 each AIDS patient was admitted to a hospital an average of 1.7 times for an average length of hospitalization of 13.0 days. The average charge per hospital day was $740. The average outpatient charge was estimated at $2,015 for each AIDS case in 1984.

The total economic impact of the first 10,000 cases of AIDS in the U.S. has been estimated at $6.3 billion, including $1.4 billion on direct hospitalization expenses, $189 million in lost wages due to disability and $4.6 billion in lost earnings from premature death.

The direct economic costs of AIDS in 1985 have been estimated at a total of $836.5 million, including $517.4 million in personal medical care costs and $319.1 million in non-personal costs (research, blood screening, education and prevention services).

The indirect economic costs of AIDS in 1985 were estimated at $3,285.6 million, including $205.7 million in morbidity costs (value of productivity losses due to illness and disability) and $3,079.0 million in mortality costs (value of earnings lost due of premature death).

According to these estimates, the total direct and indirect costs of AIDS in 1985 were $4,122.1 million.

In 1984, total personal health care expenditures in the U.S. were estimated at $387.4 billion, and total indirect costs of morbidity and mortality of all illness and death were estimated at $304.7 billion, for a total of $692.1 billion in direct and indirect costs. Estimates of the direct and indirect costs of AIDS for 1984 total $1.9 billion, a fraction of 1% of the total economic costs for all diseases that year.

Expenditures for Research on AIDS

Research expenditures on AIDS have increased from $60 million in 1984 to $113.6 million in 1985 to $233.7 million in 1986.

The expenditures for AIDS health education, information and support services by the Centers for Disease Control, State and local governments and community-based volunteer organizations have been estimated at $19.3–$23.3 million for 1985 and $27.6–$31.6 million for 1986.

In one of the most promising developments in more than 20 years, scientists say that drugs used to control HIV / AIDS in the patients may also effective in preventing the disease in the first place.

The drug in question tenofovir (Viread) and emtricitabine, FTC (Emtriva), in combination as Truvada by Gilead Sciences Inc. Gilead is the California company known for the invention of Tamiflu.

The research was on the search for a vaccine against HIV / AIDS, with the intention to air-conditioning the immune system against the disease. But these drugs work differently. They simply keep the virus from reproducing, and has already been successfully used by medical workers to prevent them from getting infected by the virus, of the patients.

This approach to the fight against HIV / AIDS researchers was tempting for many years, but has only recently been possible, preventive drugs have been developed that are safe for non-infected persons should be taken. Previous drugs had unreasonable consequences for the non-infected people.

This situation changed with tenofovir came on the market in 2001. Tenofovir is powerful and safe, and there must be only once a day. It has also not with other medicines or birth pill, and manifested less resistance than other AIDS drugs drugs.

Monkey studies show exciting results

A large study by the CDC (Center for Disease Control and Prevention) in Atlanta, Georgia, the six macaques. The monkeys were given a combination of tenofovir and FTC, and then administered a lethal combination of monkey and human AIDS viruses. They were given the virus in rectal doses to simulate contact between gay men.

Each received 14 weekly exposure to the virus, and none of the monkeys became infected. In a control group who do not have the drugs, all but one got the disease, usually after only two claims.

The scientists then stopped, the drug in the group test, to see if the prevention was only temporary. The results were equally impressive. None of the monkeys by the disease. "We are now four months after the animals no drugs, no virus. You are not infected and healthy, "said a CDC researcher.

Now for other research teams insist that this combination tested on humans. A $ 29 million CDC study of drug users in Botswana is now on this new combination.

Another study of 400 heterosexual women in Ghana by Family Health Initiative, and financed by the Bill and Melinda Gates Foundation, is studying the effects of tenofovir alone.

But some other studies did not materialize because studies of this nature immediately suspected that the scientists with the local population as guinea pigs. The fear is that they intentionally expose the volunteers to the virus.

The cost of tenofovir and Truvada also testing difficult. In the African countries, condoms are now generous donations from companies that help the organizations of the United Nations and Western governments. While the drugs are comparatively cheap, the cost remains an obstacle.

Yet researchers were new of the impressive results from Atlanta, and new tests go further into the pockets of interest around the world.

CDC Recommends HIV Tests, Puts Less Stress on Condom Use

In a significant shift in strategy for the fight against HIV / AIDS, the Centers for Disease Control recently recommended that tests for HIV be extended to all patients in hospitals and clinics in the U. S. The CDC also recommended that the doctors begin with routine voluntary HIV testing for patients between 13 and 64 years.

It is estimated that of the more than one million people in the United States with HIV and AIDS, approximately 25% are unaware that they have HIV. The new strategy aims to discover such cases before HIV develops into AIDS. It is also hoped that these measures be taken to stop the spread of the disease, because these 250,000 people are carriers who unknowingly infect.

This is a departure from the hitherto followed strategy of the test only people in high-risk groups.

This policy change is also a departure from the promotion of abstinence and the use of condoms to prevent the spread of the disease, including more emphasis on the tests for HIV status, and early treatment.

According to a spokesman for the CDC, explains what this change in policy is that drugs now available, can prevent the development of AIDS from HIV. Early detection can be in the early treatment. In the past, early detection does not necessarily mean a lot, because it is only very little could be done that for someone infected with HIV.

It is also hoped that the early detection is less transmission of the disease. A recent survey revealed that CDC sexually active adults changed their sexual behavior patterns after they were diagnosed with HIV. They were less likely to be in unprotected sexual activities, in many cases, for a condom or not for themselves in sex at all.

Drug companies and makers of the oral exams are to benefit substantially from this shift of emphasis. It is expected that the tests that are now on the management of hospitals and clinics will soon be available over the counter. Interested in the test phase itself in a position to do at home. This should result in a significant increase in the sale of HIV test kits.

There should also be a rise in HIV drug treatment as hundreds of thousands of people learn they have HIV and begin treatment with antiretroviral drugs. Currently, antiretroviral drugs for approximately $ 6 billion in sales in the U. S. This number will increase dramatically if the new testing methods prove to be effective.

Some argue that, as in so many areas in the healthcare industry, the efforts on prevention will be replaced by promise of a quick cure to us compliments of the incredibly powerful and increasingly invasive drug.

AIDS/HIV Information

AIDS, which stands for Acquired Immunodeficiency Syndrome it causes destruction of the immune system. It is the most advanced stage of the HIV virus (HIV stands for Human Immunodeficiency Virus). AIDS is defined by the Centers for Disease Control and Prevention (CDC), such as the presence of a positive HIV antibody test, and one or more of the diseases known as opportunistic infections.

The HIV virus, type 1 or 2 is generally known that the cause of AIDS. HIV attacks and breaks down your T-cells, so that your body is not able to take out various infections. The HIV virus attacks your peripheral nervous system, it causes nerve and muscle pain, especially in the feet, legs and hands.

HIV is spread through direct contact with blood or semen of a person who is infected. This can be done in many ways is the most frequent unprotected sexual intercourse. Other means of infection are infected blood transfusions, the mother to child (at the time of birth or through breast milk), sharing needles with an infected person, and only rarely the health professions that workers receive pricked with a needle infected.

Often people who are infected with HIV to have some symptoms, and in some cases there are none. Other times, the symptoms of HIV with other illnesses such as the flu. This can be severe, with swollen glands in the neck and armpits, fatigue, fever and night sweats. That is where as many as 9 out of 10 of the infected people will develop AIDS. At this point the person feels completely healthy and not even know that he or she has the virus. The next phase begins when the immune system begins to break and the increasingly aggressive virus in the white cells damage. Several glands in the neck and armpits May swell and remain swollen for a longer period of time without any explanation. As the disease progresses, or warts can be cooked over the body. You can also feel tremendously tired, night sweats, high fever, chronic diarrhea, and they lose a significant portion of their body weight. Most of the cases have shown chokes as a symptom as well. At this point the person is in the final stages of HIV / AIDS. Severe chest infections with a high fever, and the survival is about 70%, but reduced with each repetition.

A person is diagnosed with AIDS if he or she has 01 or more positive HIV screening and the presence of a definition of AIDS condition. Some of the usual conditions include but are not limited to: meningitis, encephalitis, dementia, pneumonia, Kaposi sarcoma and lymphoma. There is also a blood test for a so-called immunotherapy profile that can be done. This test is intended to measure the loss of immunity and help decide on the best treatment. It is a test, which is rarely used because of its high cost, it is known as viral load: This test detects the virus itself, and also measures the amount of HIV in the blood. It shows how quickly the HIV infection is likely. A high viral load suggests that the person can quickly AIDS.

Although there is no cure for AIDS, there are medical treatments, help in the renewal and the preservation of the best quality of life possible. These include two nucleoside inhibitors, lamivudine and zidovudine. Current treatment plans will vary with each patient, along with the physical aspect of this disease. The psychological side has the contract for a treatment plan to be effective.

The easiest way to escape contracting this disease is that the risk factors that you are in control. For example, unprotected sex, not sharing with a needle, and if you are in the area of health care, ensure that all necessary precautions to avoid an accidental prick of a needle infected possible (not forget that at this early stage disease it is usually, the person does not even know they are infected). AIDS is now the fifth leading cause of death among adults aged 25 to 44 in the United States. Among African-Americans in the 25 to 44 years, AIDS is the leading cause of death among men and the second leading cause of death among women. Our society must be aware that we are not to protect us, we kill them, and that it will stop.